Scarica l'app Stockscreener
18.85
1.24%
0.23
Pre-mercato:
18.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$18.62
Aprire:
$18.87
Volume 24 ore:
2.56M
Relative Volume:
1.51
Capitalizzazione di mercato:
$2.26B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-4.8087
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
+7.10%
1M Prestazione:
+21.46%
6M Prestazione:
+20.52%
1 anno Prestazione:
+102.69%
Intervallo 1D:
$18.62
$19.36
Intervallo di 1 settimana:
$16.57
$19.36
Portata 52W:
$8.03
$19.36
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
18.85 | 2.23B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Will Arcutis Biotherapeutics Inc. stock split attract more investorsEarnings Growth Summary & Reliable Price Breakout Signals - newser.com
Dermatology Leader Arcutis Announces Strategic Growth Plan Reveal at October Investor Day - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week HighWhat's Next? - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 18.17 USD By Investing.com - Investing.com Canada
Arcutis Biotherapeutics stock hits 52-week high at 18.17 USD - Investing.com India
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - Yahoo Finance
What drives Arcutis Biotherapeutics Inc stock priceEx-Dividend Date Alerts & High Yield Trading Growth - earlytimes.in
Is Arcutis Biotherapeutics Inc. stock reversal real or fakeWeekly Trend Report & Community Trade Idea Sharing Platform - newser.com
Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy - Yahoo Finance
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Share Price Not Quite Adding Up - 富途牛牛
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Exploring a 30.94% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 4.5% HigherHere's What Happened - MarketBeat
29,244 Shares in Arcutis Biotherapeutics, Inc. $ARQT Purchased by Triumph Capital Management - MarketBeat
Bull Run: Why is Arcutis Biotherapeutics Inc. stock going upQuarterly Market Review & Real-Time Chart Pattern Alerts - خودرو بانک
Published on: 2025-09-20 11:38:58 - خودرو بانک
Stock Analysis: Is Arcutis Biotherapeutics Inc stock good for income investors2025 Trading Volume Trends & Weekly Chart Analysis and Guides - خودرو بانک
Analyst Upgrade: What is Arcutis Biotherapeutics Inc. s 5 year growth outlookTrade Entry Summary & Community Driven Trade Alerts - خودرو بانک
EPS Watch: Can Viavi Solutions Inc maintain its current growth rateEarnings Risk Report & Weekly High Conviction Trade Ideas - khodrobank.com
Breakout Move: Can Arcutis Biotherapeutics Inc sustain earnings growthJuly 2025 WrapUp & Safe Swing Trade Setup Alerts - خودرو بانک
Take Profit: What are the future prospects of Arcutis Biotherapeutics IncQuarterly Risk Review & Stepwise Trade Execution Plans - خودرو بانک
Anti-Aging Market Surges as $101M Competition Drives Demographic Revolution - baystreet.ca
Income Plays: Will FBLA face regulatory challengesRecession Risk & Reliable Intraday Trade Alerts - خودرو بانک
Invst LLC Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis director Howard G. Welgus sells $127,100 in common stock - MSN
Market Review: Is ProShares Trust ProShares UltraPro Short S&P500 a good ESG investmentJuly 2025 WrapUp & Expert-Curated Trade Recommendations - خودرو بانک
CEO Change: Can NanoViricides Inc continue delivering strong returnsWeekly Risk Summary & Safe Entry Zone Tips - خودرو بانک
Arcutis Biotherapeutics (ARQT) Unveils Positive Data on Zoryve F - GuruFocus
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress - The Manila Times
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress | Dow Theory Letters - FinancialContent
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award - GlobeNewswire
79.5% Success Rate: Arcutis' ZORYVE Foam Proves Highly Effective for Seborrheic Dermatitis Across All Skin Types - Stock Titan
Fred Alger Management LLC Invests $568,000 in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
FOMO Trade: Does Arcutis Biotherapeutics Inc stock reflect fundamentals2025 Sector Review & Low Drawdown Trading Techniques - خودرو بانک
Arcutis Biotherapeutics’ ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Award for Innovation in Dermatology - Quiver Quantitative
Aug Big Picture: Can Arcutis Biotherapeutics Inc stock outperform in a bear market2025 Dividend Review & AI Enhanced Trading Signals - خودرو بانک
#1 Prescribed Dermatology Treatment ZORYVE Wins Prestigious Allure Award for Revolutionary Skin Care - Stock Titan
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 9,625 Shares - MarketBeat
Aug Reactions: Will Arcutis Biotherapeutics Inc. benefit from current market trendsMarket Performance Summary & Weekly Top Stock Performers List - خودرو بانک
Chipmakers Recap: Can Arcutis Biotherapeutics Inc sustain earnings growthJuly 2025 Reactions & Reliable Momentum Entry Alerts - خودرو بانک
What are analysts price targets for Arcutis Biotherapeutics Inc2025 Retail Activity & Safe Swing Trade Setup Alerts - خودرو بانک
Fund Flows: What are analysts price targets for Arcutis Biotherapeutics IncQuarterly Investment Review & Daily Profit Maximizing Tips - خودرو بانک
Market Outlook: Is Arcutis Biotherapeutics Inc. forming a bullish divergence2025 Technical Overview & Consistent Income Trade Recommendations - خودرو بانک
Earnings Risk: Is National Presto Industries Inc gaining market shareEarnings Summary Report & Consistent Profit Focused Trading Strategies - khodrobank.com
Published on: 2025-09-15 14:30:32 - خودرو بانک
Arcutis Biotherapeutics (NASDAQ:ARQT) Sets New 1-Year HighHere's Why - MarketBeat
What MACD signals say about Arcutis Biotherapeutics Inc.2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - newser.com
Arcutis Biotherapeutics Inc. stock trend forecastPortfolio Value Report & Stock Portfolio Risk Control - newser.com
Measuring Arcutis Biotherapeutics Inc.’s beta against major indicesJuly 2025 Final Week & High Accuracy Trade Signal Alerts - newser.com
Arcutis Biotherapeutics Inc. stock volume spike explainedTrade Signal Summary & Smart Swing Trading Alerts - newser.com
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):